Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03084014 monotherapy in advanced triple-negative breast cancer with or without Notch receptor genomic alterations
2014-002286-30Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nirogacestat in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Pfizer. Primary endpoint: Objective response in Notch alteration-positive metastatic triple-negative breast cancer. Started Oct 2014; status: terminated.
02
Drugs
nirogacestat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-002286-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002286-30.